Lobular Carcinoma in Situ

Lobular carcinoma in situ is a proliferation of atypical, non-invasive epithelial cells confined within the breast lobules, without invasion through the basement membrane.

It is not a direct malignant precursor in the way ductal carcinoma in situ is a precursor to invasive ductal carcinoma. It is a marker of substantially increased, bilateral future breast cancer risk.

This distinction is fundamental to management. Lobular carcinoma in situ does not need the direct treatment applied to ductal carcinoma in situ (surgical excision aiming for clear margins, with consideration of radiotherapy). It warrants risk-reduction and enhanced surveillance, because it is a risk marker and not an obligate precursor.

Pathophysiology and classification

• The lesion is a proliferation of small, relatively uniform, discohesive epithelial cells that fill and distend the breast lobules. It is typically characterised by loss of E-cadherin expression. E-cadherin is a cell adhesion molecule. Its absence in lobular carcinoma in situ and invasive lobular carcinoma distinguishes them immunohistochemically from the ductal lineage, where E-cadherin expression is retained.
• The lesion is frequently multifocal and bilateral, unlike ductal carcinoma in situ, which more typically presents as a unifocal, unilateral lesion. This fits the risk-marker framework: the increased future breast cancer risk applies to both breasts, not just the site of the identified lesion.
• Classic lobular carcinoma in situ is associated with an approximately seven to twelve fold increased relative risk of subsequent invasive breast cancer compared with the general population. The risk applies to either breast, reflecting the field-change, bilateral nature of the lesion, and persists over an extended period after diagnosis. This differs from the more localised, site-specific risk of ductal carcinoma in situ.
• Pleomorphic lobular carcinoma in situ is a less common, more cytologically atypical variant. It is increasingly recognised to behave differently from classic lobular carcinoma in situ. Some evidence suggests a closer biological relationship to ductal carcinoma in situ, and some contemporary guidance supports more active management, including surgical excision, for this variant.

• Lobular carcinoma in situ is characteristically asymptomatic and produces no distinguishing mammographic finding of its own. The great majority of cases are identified incidentally on core needle biopsy performed for an unrelated indication, including biopsy of a different, coincidentally identified benign or indeterminate lesion.
• There is no characteristic palpable mass or mammographic abnormality attributable to the lesion. This differs from ductal carcinoma in situ, which frequently presents with microcalcification on mammography.
• Because the diagnosis is typically incidental, it frequently causes significant patient anxiety and confusion. The term "carcinoma" in its name is alarming, yet its biological behaviour as a risk marker differs fundamentally from that of a direct cancer precursor. Clear, accurate patient education and communication about the nature of the diagnosis are important.

• Diagnosis is established by histopathological examination of breast tissue. It is most commonly identified incidentally on core needle biopsy performed for an unrelated indication, and less commonly on examination of a surgical excision specimen performed for a different, primary indication.
• A more significant lesion (ductal carcinoma in situ or invasive carcinoma) may coexist at the same or an adjacent site. This is relatively uncommon, but is particularly relevant where lobular carcinoma in situ is found on core needle biopsy rather than on a surgical excision specimen.
• Surgical excision of the biopsy site is therefore frequently recommended after a core biopsy diagnosis of lobular carcinoma in situ. It aims to exclude associated, more significant pathology not represented on the core sample. The recommendation varies with histological subtype (classic versus pleomorphic) and the degree of imaging-pathology concordance.
• Full breast imaging supports assessment of both breasts, given the bilateral risk implications. It includes mammography and, where individual risk factors indicate, breast magnetic resonance imaging. The lesion itself does not produce a characteristic mammographic abnormality.

• Once any associated, more significant pathology has been excluded, classic lobular carcinoma in situ is generally managed with risk-reduction and enhanced surveillance. It does not need further surgical excision aiming for clear margins, because the lesion is a bilateral risk marker and not a localised cancer precursor requiring complete local excision.
• Enhanced breast cancer surveillance is standard. It involves more frequent clinical breast examination and mammographic screening than standard average-risk population protocols. Supplementary breast magnetic resonance imaging screening is considered for appropriately selected higher-risk women. It follows established high-risk surveillance protocols and individualised risk assessment.
• Risk-reducing pharmacological therapy is an evidence-based option for appropriately selected women, with a meaningful reduction in subsequent breast cancer risk. Options are selective oestrogen receptor modulators (including tamoxifen) or aromatase inhibitors. Agent and duration are individualised according to menopausal status and the risk-benefit profile.
• Bilateral risk-reducing mastectomy is a more radical option, highly effective but substantial. It is generally reserved for women with a particularly elevated overall risk, such as lobular carcinoma in situ together with a strong family history or a confirmed pathogenic genetic mutation. Offer full, individualised counselling first.
• Pleomorphic lobular carcinoma in situ generally warrants more active management, because its biological behaviour is somewhat distinct. Surgical excision aiming for clear margins is frequently recommended, more closely paralleling the approach to ductal carcinoma in situ, which this variant more closely resembles biologically.
• Clear patient education should explain that lobular carcinoma in situ is a risk marker and not a direct cancer precursor. Consider genetic counselling where additional risk factors are present. Plan structured, ongoing risk assessment and surveillance.